Stern Cardiovascular Foundation, Inc.

Summary

Stern Cardiovascular Foundation, Inc. is a medical facility located in Germantown, Tennessee. This center is recognized for care of Heart Failure, Cardiovascular Disease, Atrial Fibrillation, Heart Attack, Stroke and other specialties. Stern Cardiovascular Foundation, Inc. is involved with conducting 56 clinical trials across 72 conditions. There are 3 research doctors associated with this hospital, such as Frank McGrew, M.D., John Jeffries, MD, and John Lynn Jefferies.

Top PIs

Clinical Trials running at Stern Cardiovascular Foundation, Inc.

Heart Failure

High Blood Pressure

Obesity

Atrial Fibrillation

Peripartum Cardiomyopathy

Cardiomyopathy

Childhood Obesity

Atherosclerosis

Cardiovascular Disease

Systolic Hypertension

Spironolactone

for Heart Failure

Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduces the composite of CV mortality and HF hospitalization as follows: Population: HFPEF patients in the Swedish Heart Failure Registry and HFPEF patients in US. HFPEF defined as symptoms/signs of HF, elevated NTproBNP (B-type Natriuretic Peptide; N-terminal pro b-type Natriuretic Peptide) and EF\>=40%. Intervention and control: Randomized 1:1 to intervention: spironolactone + usual care vs. control: usual care alone. Outcome: Primary outcome cardiovascular death or time to HF hospitalization. Secondary outcomes include hospitalization for various causes, adverse events and treatment adherence. In Sweden outcomes are obtained automatically by linking with the Population, Patient and Drug Dispensed Registries. In the US, outcomes will be reported by sites and supplemented by data from a call center. The trial is event-driven with enrollment 7 years and study duration 9 years. For the primary outcome (CV Death or first HF hospitalization) with an event target of 721 events the sample size requires 1985 patients conservatively rounded to approximately 2000 patients.

Recruiting

3 awards

Phase 3

7 criteria

Omecamtiv Mecarbil

for Heart Failure

The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

Recruiting

1 award

Phase 3

10 criteria

CCM Therapy

for Heart Failure

This trial tests a device that helps the heart pump better in patients with moderate heart failure. It targets those whose heart's pumping ability is moderately reduced. The device works by giving the heart small electrical boosts. Several new devices for the treatment of heart failure patients have been introduced and are increasingly used in medical practice or are under evaluation.

Recruiting

0 awards

N/A

7 criteria